Neumora Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

NMRA$0.47-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Convertible Preferred Stock Stockholders' Equity (Deficit)

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands)

ConvertiblePreferred Stock · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensiveGain · Accumulated · TotalStockholders'Equity
	Shares	Amount	Shares	Amount	Capital	(Loss)	Deficit	(Deficit)
Balance as of December 31, 2021	94,710	$729,858	31,985	$3	$11,381	$—	$(336,605)	$(325,221)
Issuance of Series A-1 convertible preferred stock upon exercise of warrants	157	1,613	—	—	—	—	—	—
Issuance of Series B convertible preferred stock, net of issuance costs of $179	9,550	112,216	—	—	—	—	—	—
Issuance of common stock upon early exercise of stock options	—	—	442	—	—	—	—	—
Issuance of common stock upon exercise of stock options	—	—	228	—	612	—	—	612
Issuance of common stock as noncash consideration related to acquisition of assets	—	—	5	—	24	—	—	24
Forfeiture of restricted stock subject to repurchase	—	—	(48)	—	—	—	—	—
Vesting of restricted common stock	—	—	—	—	1,115	—	—	1,115
Unrealized loss on marketable debt securities	—	—	—	—	—	(774)	—	(774)
Stock-based compensation	—	—	—	—	8,298	—	—	8,298
Net loss	—	—	—	—	—	—	(130,904)	(130,904)
Balance as of December 31, 2022	104,417	$843,687	32,612	$3	$21,430	$(774)	$(467,509)	$(446,850)
Conversion of convertible preferred stock into common stock upon initial public offering	(104,417)	(843,687)	104,417	10	843,677	—	—	843,687
Issuance of common stock upon initial public offering, net of offering costs of $23,546	—	—	14,710	1	226,523	—	—	226,524
Issuance of common stock upon achievement of milestone related to acquisition of assets	—	—	6,072	1	58,538	—	—	58,539
Issuance of common stock upon exercise of stock options	—	—	972	1	2,855	—	—	2,856
Sale and issuance of common stock	—	—	127	—	810	—	—	810
Issuance of restricted common stock subject to repurchase	—	—	382	—	—	—	—	—
Repurchase of unvested early exercised stock options	—	—	(123)	—	—	—	—	—
Forfeiture of restricted stock subject to repurchase	—	—	(337)	—	—	—	—	—
Vesting of restricted common stock	—	—	—	—	1,497	—	—	1,497
Unrealized gain on marketable debt securities	—	—	—	—	—	698	—	698
Stock-based compensation	—	—	—	—	17,240	—	—	17,240
Net loss	—	—	—	—	—	—	(235,925)	(235,925)
Balance as of December 31, 2023	—	$—	158,832	$16	$1,172,570	$(76)	$(703,434)	$469,076
Issuance of common stock upon exercise of stock options	—	—	1,957	—	7,482	—	—	7,482
Issuance of common stock under employee stock purchase plan	—	—	52	—	427	—	—	427
Issuance of common stock through at-the-market transactions net of offering costs $0.8 million	—	—	885	—	13,598	—	—	13,598
Forfeiture of restricted stock subject to repurchase	—	—	(99)	—	—	—	—	—
Vesting of restricted common stock	—	—	88	—	—	—	—	—
Vesting of common stock subject to repurchase	—	—	—	—	140	—	—	140
Repurchase of unvested early exercised stock options	—	—	(5)	—	—	—	—	—
Unrealized gain on marketable debt securities	—	—	—	—	—	138	—	138
Stock-based compensation	—	—	—	—	39,990	—	—	39,990
Net loss	—	—	—	—	—	—	(243,787)	(243,787)
Balance as of December 31, 2024	—	$—	161,710	$16	$1,234,207	$62	$(947,221)	$287,064

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.